Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics

Patricia Lee, MLS; David DiPersio, PharmD; Rebecca N. Jerome, MLIS, MPH; Arthur P. Wheeler, MD

See end of article for authors’ affiliations. DOI: 10.3163/1536-5050.95.4.374

THE CASE

At morning rounds in your hospital’s intensive care unit, a resident from the team presents a 55-year-old woman (weight 129 lbs) with a past medical history of multiple sclerosis, cerebellopontine angle meningioma, hypothyroidism, and a neurogenic bladder requiring a Foley catheter. This patient was transferred from her nursing home 3 days ago with a fever and altered mental status. Results from the nursing home bacterial culture of the patient’s urine revealed Gram negative rods. Bacterial culture of blood drawn from her peripheral intravenous (IV) line at the nursing home indicated Gram positive cocci. Blood cultures redrawn upon hospital admission are still pending and require confirmation.

According to the patient’s chart, she began empiric treatment at the nursing home with vancomycin (1,000 milligrams [mg] intravenously every 12 hours) and piperacillin-tazobactam (3.375 g IV every 6 hours) for urosepsis 4 days ago. The patient’s current serum creatinine is 0.56 micrograms per deciliter (mg/dL) (normal range: 0.6–1.1 mg/dL) [1], and her estimated creatinine clearance is 104 milliliters per minute (mL/min) (normal range: 88–128 mL/min) [2]. Her current body temperature is 97.2°F Fahrenheit. Today is day 4 of this patient’s vancomycin and piperacillin-tazobactam regimen and hospital day 3.

In reviewing the plan for the next twenty-four hours, the attending physician notes that the patient currently has a standing order for a laboratory test of the vancomycin trough level in her serum, with the blood sample to be taken just prior to the next dose of the drug. On day three of antibiotic therapy, the patient’s serum vancomycin trough level was eleven mcg/mL, and, on day four, the trough was eighteen mcg/mL. The institution’s target range for the serum trough level of vancomycin is five to twenty mcg/mL.

The attending physician initiates a discussion with the team—including a fellow, three residents, a pharmacist, a dietitian, the unit’s nurses, and you, as the team’s librarian—about monitoring of vancomycin. The clinician queries the team about the rationale for the standing order for vancomycin trough monitoring. The residents indicate that they often order this lab test supporting or disproving the practice of routine monitoring of trough levels in patients being treated with vancomycin in the adult critical care setting. Figures 1 and 2 provide elaboration from the team’s attending physician and pharmacist on the significance of this question to clinical practice on the unit.

THE QUESTION

Is there evidence that monitoring serum vancomycin trough levels prevents drug toxicity and/or ensures therapeutic dosing of the drug?

UNDERSTANDING THE CONCEPTS

Before you begin your literature search, you first consider the nuances of this patient’s case, described further in Table 1. She is a nursing home resident and has significant comorbidities including a benign brain tumor and multiple sclerosis with unknown disabilities. The etiology of her currently altered mental status is unknown, but nursing home staff reports it to be a change from her baseline condition. The presence of a Foley catheter is a risk factor for a urinary tract infection; however, this patient’s diagnosis of urosepsis, referring to a serious systemic infection caused by bacteria originating in the urinary tract, is much more severe and demands aggressive therapy [12]. The data presented on rounds also indicate that the patient is not obese, an important consideration for both drug dosing and prognosis. Also, her serum creatinine and estimated creatinine clearance are normal, suggesting that the patient does not have renal impairment.

In addition to developing familiarity with this patient’s specific circumstances, understanding a few basic pharmacokinetic concepts and the therapeutic agent being used in this case will aid you in searching, reading, and interpreting the literature. Peak and trough values are important concepts in understanding drug disposition, the way an individual therapeutic agent or drug distributes in and is managed by the human body. The peak level refers to the predicted highest concentration between doses, and the trough refers to the lowest predicted concentration just before the next dose. Serum levels of the antibiotic must be high enough during the dosing interval (i.e., the period in between doses of the agent) to kill the infecting organism and prevent further growth. After IV dosing, a drug may be distributed throughout the body, may only target certain organs, or may not be absorbed at certain sites. Knowing the pattern and timing of drug distribution is vital to identifying correct dosing intervals. In critical care, in which an infection typically needs to be treated aggressively to avert significant patient morbidity and mortality, clinicians attempt to
infuse the highest possible dose as rapidly as possible without causing side effects. Understanding the pharmacokinetics of an antibiotic helps to effectively treat the infection and prevent adverse effects.

Developing a better understanding of the history of this agent may also help guide your literature search and interpretation of the citations you find. Vancomycin was approved for use in the United States by the Food and Drug Administration (FDA) in 1958 for treating penicillin-resistant *Staphylococcus aureus* infection, was nicknamed “Mississippi Mud” due to its color or impurities, and was initially isolated from soil in Borneo and India [14]. Because vancomycin has been used since the 1950s, you find background information in a number of sources, with varying content and level of detail. For example, CRLonline discusses the drug’s mechanism of action and pharmacodynamics and provides a dosage recommendation [15]. This text also provides reference ranges for laboratory monitoring of patients being treated with vancomycin, recommending timing of blood draws to assess peak and trough levels; however, no reference to supporting evidence is provided.

The Micromedex DrugPoint summary for vancomycin [16] includes a “Monitoring” category, which cites target peak and trough levels along with a recommendation about measuring only troughs, but also lists exceptions:

| Peak and trough level monitoring is still warranted in certain high-risk patients such as those receiving concomitant nephrotoxic agents, sites of infection with difficult penetration (CNS, endocarditis), patients with rapidly changing renal function, or patients with a poor therapeutic response. [7] |

The Drug Point summary does not provide references but does include a link to a full drug monograph in DrugDex [17]. The “Pharmacokinetics” section of the monograph discusses measuring serum peak and trough and mentions a guide for therapeutic monitoring, noting that the recommendations are derived from “observations” of recommended doses and citing a 1999 study [18].

An UpToDate search of vancomycin retrieves “Vancomycin dosing and serum concentration monitoring in adults,” which includes the subsections “Serum concentration monitoring” and “Utility of monitoring serum concentration” [19]. The UpToDate review discourages routine monitoring and trough monitoring, recommending such practices if the patient has end stage renal disease and is likely to receive more than one dose of vancomycin, has other apparent instability or changes in renal function, is receiving another nephrotoxic agent, or is morbidly obese. The section describing indications for monitoring cites no supporting references, however.

At this point, you realize that there is likely to be a large body of literature discussing vancomycin dosing (over 600 references in the Micromedex bibliography alone) and the literature is likely to be controversial, due to the acknowledged lack of evidence to support monitoring. **CONSTRUCTING A LITERATURE SEARCH**

Table 2 includes example search strategies for a number of resources that may provide useful information describing vancomycin monitoring practices.

Searching the earliest years after vancomycin approval is problematic due to the lack of abstracts (eliminating a key textword source) and subheadings. The majority of the 1950–1965 OLDMEDLINE citations [20] have been incorporated into PubMed, and a recent NLM Technical Bulletin news item notes that the Other Terms (subject terms from the original print indexes) have been mapped to Medical Subject Headings.
Web of Science TS

| Table 1 | Key concepts for this case’s medical concepts |
|---------|--|
| **Vancomycin** | A large glycopeptide (a short chain of amino acids with sugar molecules attached) that binds irreversibly to the cell wall. Vancomycin is generally used to treat infections caused by Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile*, but resistance to vancomycin in these bacteria has been reported. Most Gram-negative bacteria are resistant, and vancomycin-resistant *Enterococcus* (a Gram-positive organism) have also been reported in association with overuse of vancomycin [6]. |
| **Pharmacokinetics: peak and trough** | The absorption, distribution to target organs, and elimination of drugs from the body. A peak level refers to the maximum concentration measured at a specific point after dosing. The trough refers to the drug concentration at the lowest point just before the next scheduled dose [7]. |
| **Creatinine clearance rate** | Measure of effectiveness of the kidney to filter creatinine, a waste product, from the blood. This estimate is used to monitor patients for potential kidney dysfunction. Creatinine clearance is expressed as milliliters per minute (mL/min) [2]. |
| **Clearance** | Refers to the body’s ability to eliminate a drug and is affected by the patient’s disease process, age, weight, and/or other agents the patient is receiving [7]. |
| **Drug monitoring** | Measurement of a specific drug in a body fluid (e.g., blood serum) at standard intervals, with the goal of adjusting drug dosage as necessary to maintain a constant level or concentration (steady state). Regular monitoring is usually employed when an agent’s specific “therapeutic range” is narrow between effective therapy and toxicity [3, 8]. |
| **Cerebellopontine angle meningioma** | Meningiomas are classified as benign tumors comprising cells lining the arachnoid villae (the apparatus responsible for absorption of cerebrospinal fluid). Typical presenting symptoms might include tinnitus, hearing loss, vertigo, ataxia, headache, or facial weakness; the primary treatment for these tumors is surgery. Incidence increases with age, and more women are affected compared to men [9]. Location of the meningioma in the cerebellopontine angle may lead to hearing loss and facial nerve findings on MRI [10]. |
| **Neurogenic bladder** | A urinary dysfunction in which the bladder does not void properly, caused most commonly by a nervous system tumor, injury to nerves supplying the urinary tract, or inflammatory conditions such as multiple sclerosis [11]. |
| **Urosepsis** | A severe infection in the genitourinary tract usually occurring as a urinary catheter–related or other health care–associated infection after invasive genital-urinary procedures [12]. |
| **Urine culture** | To examine a patient’s urine for the presence of bacteria, a urine specimen is placed on an agar plate and maintained at body temperature. Within 24 to 48 hours, any microorganisms present will form colonies. Further laboratory investigation identifies the bacteria and explores the organism’s sensitivity to specific antibiotics to aid clinicians in determining an appropriate course of treatment [13]. |

(MeSH) for approximately 75% of the 1.7 million OLD-MEDLINE records [21], which will likely increase the chances that a MeSH-based search strategy will still find relevant citations from this portion of the PubMed dataset. However, given that the older citations were indexed with different practices due to the nature of the print indexes (e.g., sometimes including fewer subject terms and/or subheadings), you will likely find it useful to supplement your more focused search strategies with broader strategies. For example, a classic article by Anderson et al. is currently indexed in PubMed with only the major subject term and sub-stance “Anti-Bacterial Agents” [22], necessitating your use of a much broader search than a simple vancomycin-based strategy. Due to the volume of the literature, you may want to consider these older citations separately, using the broader search only in OLD-MEDLINE to obtain a more manageable retrieval set and using the narrower search in the more recent literature.

In addition to the work by Anderson et al. noted above, other older items will likely also provide essential background information for understanding how the biomedical community’s knowledge of vancomy-
cin pharmacokinetics has evolved since the drug’s discovery in the 1950s [23–25]. Though these initial studies may not prove useful for your overall summary of the literature (discussed further below), they provide excellent insight into the origins of the vancomycin pharmacokinetic levels examined in the more recent literature.

The Fairbrother and Williams 1956 article, for example, reports testing results of vancomycin sensitivity for 1,350 organisms, including 540 strains of S. aureus, with all proving sensitive [23]. This paper notes a key limitation of in-vitro studies, however, in terms of the generalizability of the results to a clinical setting, emphasizing “in-vitro sensitivity tests do not provide an absolute criterion of clinical efficiency; they only indicate activity . . . under laboratory conditions which tend to be favorable to the antibiotic.” You also find that the limitations of generalizing the results of in-vitro studies echo through much of the literature debating the utility of therapeutic drug monitoring in patients receiving vancomycin [24–27].

Another example of an early in-vitro study of vancomycin’s effects is provided by a 1956 paper by Geraci et al. examining Micrococcus pyogenes in several populations, both human and animal, detailing measurement of vancomycin concentrations in body fluids after both IV and oral dosing and examining the sensitivities of multiple pathogens [28]. These investigators established that a serum vancomycin concentration of 2.5 mcg/mL completely inhibited 110 of 112 strains of M. Pyogenes. This finding became an important standard established for vancomycin sensitivity for many organisms, despite the lack of validation in subsequent clinical trials, providing some insight into the weaknesses of the evidence base supporting vancomycin dosing and monitoring practices.

A 1970 study by Washington et al. is key due to the authors’ perspective on vancomycin dosing and monitoring. These authors noted there was no experimental evidence or even “universal agreement” defining in-vitro susceptibility or resistance of a microorganism to an antibiotic [29]. Washington went on to say that as a general rule if the antibiotic blood levels exceeded the in-vitro MIC level by two to four times, then “the organism is usually considered to be sensitive.” As with the work by Geraci et al., this study highlights the way in which experimental in-vitro results became the foundation for clinical practice in vancomycin monitoring and dosing, without the strength of validation through clinical trials.

In addition to understanding the growth of the vancomycin-related literature by examining these older citations, perusing the bibliographies of the relevant articles you identify during your searching process is another way to find additional items not retrieved by your search strategy. Though it can be considerably time consuming, this hand-searching step is essential if you wish to conduct a comprehensive search and produce a high-quality and thorough end product.

As you scan through your search retrieval sets, you realize that a number of studies examine the use of vancomycin without quantitative sensitivity or pharmacokinetic data. Such studies may be useful to support selecting vancomycin as a therapeutic agent but omit data that would support informed clinical decision making about how or when such patients should be monitored during vancomycin therapy. In your results, you also note a lack of clinical trials examining correlation between vancomycin monitoring and clinical outcomes, finding that most primary data on the topic focus on either laboratory testing results or retrospective considerations of vancomycin pharmacokinetics in critically ill populations.

Of the items you peruse in your search results, you focus most closely on the studies that include either in-vitro sensitivity data or research examining associations between therapeutic drug monitoring and clinical outcomes (e.g., duration of therapy, cumulative dose, resolution of infection, mortality) in adult patients receiving vancomycin. You also consider key opinion pieces and guideline statements to reflect areas of consensus and debate related to laboratory monitoring during vancomycin therapy. To address the question, you select a final group of articles including a set of practice guidelines that contain recommendations for vancomycin monitoring [30], a review that provides an excellent summary of the debate surrounding this issue [31], and several studies from more recent years that yield in-vitro and observational clinical data illustrating potential utility and limitations of vancomycin monitoring [32–39].

SUMMARIZING THE LITERATURE

One of your key challenges in summarizing this literature lies in illustrating for the clinical team the areas of consensus and debate related to this question. Figure 3 provides a sample overall summary of the literature, beginning with a synthesis of the perspective you developed in your detailed examination of the older literature from the time period closer to the Food and Drug Administration’s approval of vancomycin for use in the United States, followed by brief summarization of:

- a set of 2005 practice guidelines from the American Thoracic Society and the Infectious Diseases Society of America, noting the rationale for the guidelines and the acknowledged paucity of evidence to inform decision making on the issue [30]
- a thorough review from 1994 that emphasized the lack of data supporting vancomycin testing practices and the potential economic impact of over-testing [31]
- individual studies highlighting various aspects of this debate [32–39]
- an overall conclusion regarding your understanding of the literature on the topic

CONCLUDING REMARKS

When you present the literature to your team, they are not surprised at your evaluation of the scant evidence to support connections between routine peak and trough monitoring and actual clinical outcomes or toxicity and realize that this is a huge and confusing lit-
Despite the fact that vancomycin has been available since the 1950s, there is a paucity of literature linking positive clinical outcomes from therapeutic drug monitoring to vancomycin drug levels. The practice of routine drug monitoring seems to be largely based on the rationale that targeting the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) [3] will provide a sufficient drug concentration over a time period to efficiently resolve an infection while reducing the potential for renal adverse effects and ototoxicity. Items included below provide insight into the limited intravenous and clinical data used to extrapolate therapeutic levels of vancomycin and their potential significance in terms of toxicity and treatment effectiveness, as well as examples of commentary noting the debate in the literature regarding the lack of evidence to inform drug-monitoring decisions in the context of patients receiving vancomycin.

In 2005, the American Thoracic Society and the Infectious Diseases Society of America published a guideline that recommends a vancomycin dose of fifteen milligrams per kilogram per twelve hours (mg/kg/twelve hrs) and a trough target concentration of fifteen to twenty mcg/mL in patients with normal kidney and liver function with health care–associated pneumonia, while acknowledging the lack of clinical data to support the recommendations [30]. Regarding the rationale for the recommendation despite the lack of evidence, the guideline notes that inadequate dosing and failure to achieve sustained serum concentrations may lead to increased resistance, progression of infection, and higher mortality.

Cantu et al. in 1994 reviewed the evidence for the effectiveness of vancomycin monitoring for peak and trough as well as toxicity, concluding that, despite the “well-entrenched” practice, there was no evidence to support cause and effect between serum level and either outcome or toxicity [31]. The investigators noted that their own institution, Johns Hopkins Hospital, performed about 6,500 assays in 1991 and estimated there were more than 5 million assays throughout the United States annually, engendering considerable cost. They recommended development of a nomogram for vancomycin dosing based on age, weight, and estimated renal function. This paper has been cited in the literature over 100 times since publication.

Several studies provide evidence further emphasizing the controversial nature of this topic and noting specific considerations in patients with current renal dysfunction or risk factors for the development of this adverse effect. Some authors also emphasize the potential utility of a nomogram to support dosing and monitoring in adult critically ill patients receiving vancomycin.

Iwamoto et al. conducted a retrospective examination of data from 184 patients with MRSA infection receiving intravenous (IV) vancomycin [32]. Investigators observed a significant decrease in creatinine clearance in the 111 patients who did not receive therapeutic drug monitoring (TDM) when compared with the 73 patients who received TDM during vancomycin therapy (P < 0.05). These results highlight the potential development of renal adverse effects in some patients receiving vancomycin without therapeutic drug monitoring.

Regarding the relationship between vancomycin serum levels and resolution of infection, a subgroup analysis in the Iwamoto et al. study examined patients with either MRSA bacteremia or pneumonia who received TDM (n = 53) to those not being monitored (n = 46). Differences in cumulative dose and duration of therapy were not significant between the two groups, but the authors noted the potential reduction in adverse effects noted in patients receiving TDM, monitoring was not associated with significant differences in either cumulative dose or duration of therapy, implying potential lack of TDM effect on drug dosing or infection.

In another important study, Karam et al. (1999) conducted a retrospective comparison among critical care and trauma patients in a 340-bed teaching hospital in Detroit [33]. A vancomycin-based practice (1) a retrospective group of 120 patients dosed by the nomogram developed by Sakoulas et al. (2004) for peak and trough values with dosing adjustments to (2) a group of 120 patients prospectively dosed between November 1996 and May 1997 using a simple vancomycin nomogram based on the patient’s weight and estimated creatinine clearance. Patients in the prospective group were excluded if their estimated creatinine clearance was < 30 mL/min and their weight < 50 kg. In the prospective group, a single trough measurement was made after day 5. If the value was 5–20 mcg/mL, no change was made; if the trough concentration was ≥ 20 mcg/mL, the dose was cut by 50%. The nomogram was validated by actual versus predicted trough concentrations. Seventy-two (94%) patients dosed by the nomogram had trough concentrations in the target range of 5–20 mcg/mL. Average duration of therapy was 9.9 ± 4.9 days in the nomogram group and 88.6 ± 7.2 days for the pharmacokinetic group. There were no statistically significant differences between the pharmacokinetic-monitored group versus the nomogram group with respect to outcome or persistence of infection, cure, improvement, failure, or toxicity. Nephrotoxicity was not significantly different between the 2 groups (18/85 in the pharmacokinetic group vs. 15/86 dosed by nomogram). Authors acknowledged that their patient population was young and the nomogram was most reliable in patients with an estimated creatinine clearance above 60 mL/min.

An in-vitro vancomycin susceptibility study by Sakoulas et al. (2004) examined 30 different MRSA isolates from 30 patients with known clinical outcomes in a phase II and IV prospective randomized clinical trial (RCT) from 16 states and 24 hospitals to determine the relationship between bactericidal activity and outcome. Peak and trough values were not considered in this study [34]. Authors speculate that the wide vancomycin killing range, with varying levels of vancomycin required to successfully destroy the isolates during laboratory testing, might be an explanation for the mixed therapeutic effectiveness results observed in clinical outcome studies of vancomycin. Of note, this study was also selected by the Faculty of 1000 (a collective of subject experts in medicine and the life sciences who rate and critique the literature—read and critiqued by physicians, pharmacists, or others—has become a catalyst for practice change in your institution. In this case, the attending physician and pharmacist concur about the existing lack of evidence and move to systematize changes in

erature. They are particularly interested in the specific articles used to support your synthesis of the literature and your skill in distinguishing real evidence from anecdotal or opinion-based recommendations and practices.

At a local charge of $250 for each peak and trough measurement for a patient receiving vancomycin, the charges for this testing combination approached $1.2 million at your institution in one recent year. Debating routine measurement of vancomycin levels and its associated costs without evidence of many benefits, as revealed by your examination of the literature in conjunction with the clinical team’s interpretation and expertise, leads to changes in your institution’s computerized provider order entry system (CPOE). To support informed clinician decision making on vancomycin monitoring, the CPOE system now advises against measuring peak values. If an order for a trough level is requested, a new popup screen called the “Vancomycin Trough Level Order Advisor” appears. The clinician must select an exception criterion (e.g., renal dysfunction, obesity, > 7 days duration of therapy, suspected treatment failure due to low serum levels) to order the drug monitoring and complete a consult form for pharmacist advice before the order is accepted. Such standardization of practices is one strategy for facilitating the systematic incorporation of evidence into clinical practices.

Your comprehensive review of the evidence in the literature—read and critiqued by physicians, pharmacists, or others—has become a catalyst for practice change in your institution. In this case, the attending physician and pharmacist concur about the existing lack of evidence and move to systematize changes in
vancomycin test-ordering practices throughout the institution. Using your skills as part of the clinical team can assist the library in proving that your services have a direct return on investment and make you a highly valued team member.

REFERENCES

1. American Society for Clinical Chemistry. Creatinine. [Web document]. The Society, 2005. [rev. 22 Jun 2005; cited 5 Jun 2007].
2. Creatinine clearance. In: MedlinePlus medical encyclopedia. [Web document]. Atlanta, GA: A.D.A.M., 2006. [rev. 3 Feb 2006; cited 5 Jun 2007].
3. Koch-Weser J. Drug therapy. serum drug concentrations as therapeutic guides. N Engl J Med 1972 Aug 3;287(5):227–31.
4. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999 Jan;47(1):23–30.
5. Jeffres MN, Isakov W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006 Oct;130(4):947–55.
6. Anderson PO, Knoben JE, Troutman WG, eds. Handbook of clinical drug data. 10th ed. Stamford, CT: Appleton & Lange, 2002.
7. Brunton L, ed. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006.
8. Lab tests online. Therapeutic drug monitoring. [Web document]. American Association for Clinical Chemistry, 2006.
9. Haddad G, Chamoun RB. Meningioma. [Web document]. Lab tests online. Therapeutic drug monitoring. [Web document]. American Association for Clinical Chemistry, 2006.
10. Conrad CB. Cerebellopontine angle meningioma. [Web document]. The Society, 2005. [rev. 22 Jun 2005; cited 5 Jun 2007].
11. Neurogenic bladder. In: MedlinePlus medical encyclopedia. [Web document]. Atlanta, GA: A.D.A.M., 2006. [rev. 14 Nov 2006; cited 5 Jun 2007].
12. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999 Jan;47(1):23–30.
13. Lab tests online. Urine culture. [Web document]. American Association for Clinical Chemistry, 2006. [rev. 11 May 2005; cited 5 Jun 2007].
14. Vancomycin. Lancet. 1957 Jan 12;272(6959):85–6.
15. Vancomycin. In: Clinical reference library online (CRLonline). [Web document]. Hudson, OH: Lexi-Comp, 2001. [rev. 23 May 2007; cited 5 Jun 2007].
16. Vancomycin. [Web document]. In: DrugPoint. [cited 5 Jun 2007]. Greenwood Village, CO: Thomson Micromedex, 2006.
17. Vancomycin. [Web document]. In: DRUGDEX. [cited 5 Jun 2007]. Greenwood Village, CO: Thomson Micromedex, 2006.
18. Wilhelm MP, Estes L. Symposium on antimicrobial agents—part XII. vancomycin. Mayo Clin Proc 1999 Sep;74(9):928–35.
19. UpToDate. Vancomycin dosing and serum concentration monitoring in adults. Waltham, MA: UpToDate.
20. National Library of Medicine. OLDMEDLINE data. [Web document]. Bethesda, MD: National Library of Medicine, 2004. [rev. 16 Mar 2007; cited 5 Jun 2007].
21. National Library of Medicine. OLDMEDLINE MeSH® mapping project—update May 15, 2007. [Web document]. NLM Tech Bull 2007 May-Jun;356. [cited 5 Jun 2007].
22. Anderson RC, Worth HM, Harris PN, Chen KK. Vancomycin, a new antibiotic. IV. pharmacologic and toxicologic studies. Antibiot Annu 1956–1957;75–81.
23. Fairbrother RW, Williams BL. Two new antibiotics; antibacterial activity of novobiocin and vancomycin. Lancet 1956 Dec 8;271(6954):1177–8.
24. Ackerman BH. Clinical value of monitoring serum vancomycin concentrations. Clin Infect Dis 1994 Dec;19(6):1180–2.
25. Catchpole C, Hastings JG. Measuring pre- and post-dose vancomycin levels—time for a change? J Med Microbiol 1995 May;42(5):309–11.
26. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003 May;23(5):643–50.
27. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994 Apr;18(4):544–6. Review.
28. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin Proc 1956 Oct 17;31(21):564–82.
29. Washington JA, Herrmans PE, Martin WJ. In vitro susceptibility of Staphylococcus and Streptococcus and influence of agarmedia on minimum inhibitory concentration. Mayo Clin Proc 1970 Jul;45(7):527–35.
30. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 Feb 15;171(4):388–416.
31. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994 Apr;18(4):533–43.
32. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003 Jun;26(6):876–9.
33. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999 Mar;19(3):257–66.
34. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellerling RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004 Jun;42(6):2398–402.
35. Faculty of 1000 Medicine. [Web document]. London, UK: Medicine Reports, 2007. [cited 5 Jun 2007].
36. Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002 Nov;20(5):326–32.
37. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006 Dec 1;63(23):2365–70.
38. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of Staphylococcal infections. Clin Microbiol Infect 2006 Jan;12(1):92–5.

39. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Berenger A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006 Oct 23;166(19):2138–44.

AUTHORS’ AFFILIATIONS

Patricia Lee, MLS, patty.lee@vanderbilt.edu, Assistant Director, Eskind Biomedical Library; David DiPersio, PharmD, david.dipersio@vanderbilt.edu, Clinical Pharmacist, Critical Care, Vanderbilt University Hospital Pharmacy; Rebecca N. Jerome, MLIS, MPH, rebecca.jerome@vanderbilt.edu, Assistant Director, Eskind Biomedical Library; and Adjunct Instructor, Biomedical Informatics; Arthur P. Wheeler, MD, art.wheeler@vanderbilt.edu, Director, Medical Intensive Care Unit, Division of Allergy Pulmonary and Critical Care Medicine; Vanderbilt University Medical Center, Nashville, TN